Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.
The intent of this Request for Proposal (RFP) is to invite investigators from across the globe to submit innovative proposals focusing in the following areas:
In addition, incorporation of the following into the proposed clinical study would be of interest: a correlative/biomarker component using paired biopsy samples (e.g pre- and post- treatment), cfDNA assessment, predictive signatures beyond gBRCAmut in advanced breast cancer (such as tumor BRCA/PALB2mut or HRD), or PK/PD biomarkers to explore potential mechanisms of resistance/response or synergistic effect.
LOI due date: Oct. 15, 2019
Geographic Scope • Global, institutions in all countries and geographic regions are eligible to apply
To be eligible: • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent) • Applicant must be affiliated with a host institution • Both early career and experienced investigators are encouraged to apply, and consideration will be given to all proposals meeting the selection criteria
• A total of $5 million USD is allocated to this research grants program • Applications will be reviewed by an independent review panel. 6-8 clinical studies will be selected for funding. • The amount of the grant Pfizer will be prepared to fund for any project will depend upon the external review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the approval notification
